1	Optimal and Safe Pain Management Approach in Ankle and Hindfoot Fractures:
2	Improving Practitioner Decision
3	Short title: Ankle and Hindfoot Fractures Effective and Safe Pain Control
4	Dr. Tashfeen Ahmad
5	FCPS, PhD
6	Assistant Professor
7	Departments of Surgery and Biological & Biomedical Sciences
8	Aga Khan University, Karachi, Pakistan
9	Contact e-mail: <u>tashfeen.ahmad@aku.edu</u>
10	Contact Number: +92-21-34864742
11	Dr. Zehra Abdul Muhammad
12	M.B.B.S., M.S.
13	Senior Instructor (Research)
14	Department of Surgery
15	Aga Khan University
16	Contact e-mail: <u>zehra.abdul@aku.edu</u>
17	Contact Number: +92-21-34864746
18	Dr. Yasir Mohib
19	M.B.B.S., FCPS
20	Assistant Professor
21	Departments of Surgery
22	Aga Khan University, Karachi, Pakistan
23	Contact e-mail: <u>yasir.mohib@aku.edu</u>
24	Contact Number: +92-21-34864350
25	Dr. Riaz Hussain

- 26 M.B.B.S., FCPS
- 27 Associate Professor
- 28 Departments of Surgery
- 29 Aga Khan University, Karachi, Pakistan
- 30 Contact e-mail: <u>riaz.lakdawala@aku.edu</u>
- 31 Contact Number: +92-21-34864753
- 32 Dr. Masood Umer
- 33 M.B.B.S., FCPS
- 34 Professor & Section Head
- 35 Departments of Surgery
- 36 Aga Khan University, Karachi, Pakistan
- 37 Contact e-mail: <u>masood.umer@aku.edu</u>
- 38 Contact Number: +92-21-34864736
- **39 Corresponding Author:**
- 40 Dr. Zehra Abdul Muhammad
- 41 M.B.B.S., M.S.
- 42 Senior Instructor (Research)
- 43 Department of Surgery
- 44 The Aga Khan University
- 45 Stadium Road, P.O. Box 3500
- 46 Karachi 74800, Pakistan
- 47 Contact e-mail: zehra.abdul@aku.edu
- 48 Contact Number: +92-21-34864746, +92 3212198901
- 49

50 Author contributions: Dr. Tashfeen Ahmad and Dr. Zehra Abdul Muhammad contributed to the study 51 Data interpretation and critical manuscript review, Dr. Zehra Abdul Muhammad contributed to the study 52 design, concept, questionnaire design, Literature search, data collection with analysis, manuscript writing, 53 data interpretation, Dr. Yasir Mohib, Dr. Riaz Hussain, and Dr. Masood Umer provided feedback with a 54 critical manuscript review.

55

56

Abstract

57 Background: Over or sub-optimal analgesic treatment leads to undesired consequences and 58 patient dissatisfaction. The study aims to assess the sub-optimal or optimal pain relief and safety 59 of routinely prescribed oral analgesic(s) at discharge and 1-week post-discharge in ankle and foot 60 fracture surgeries.

Methods: The ongoing prospective cohort study data on 54 ankle and hindfoot trauma fracture adult patients enrolled between June 2022 to July 2023 was analyzed. Post-surgery oral analgesics prescribed at hospital discharge and 1-week follow-up were stratified for assessing adverse events and pain (Visual Analogue Scale) at 1- and 2 weeks post-discharge. The relationship of age, gender, and comorbidity was analyzed by multiple logistic regression for adverse events and multiple linear regression for pain score.

Results: Median pain scores at 1- and 2-week follow-ups were 3.2 (IQR=3.0) and 2 (IQR=2.0) 67 respectively. Combinations of tramadol, acetaminophen with naproxen or diclofenac or 68 orphenadrine; and naproxen, pregabalin, with acetaminophen seemed toxic with sub-optimal pain 69 control. Similar results were for celecoxib combined with pregabalin and etoricoxib combined 70 with diclofenac or tramadol. Acetaminophen alone was safe but occasionally showed intolerance. 71 Etoricoxib or diclofenac alone or with acetaminophen was safe and showed better pain control in 72 this cohort. A regression model was non-significant for a relationship between covariates and pain 73 scores or adverse events. 74

75 Conclusion: Current data suggests that certain oral analgesics or their combinations are harmful 76 with sub-optimal pain control while some are safe and effective. Choosing suitable analgesics or 77 their combinations in specific fractures might reduce patient harm with optimal pain management.

- 78 Keywords: Ankle fracture, Hindfoot fracture, Trauma, Optimal pain management, Adverse
- 79 events, Oral analgesics.

80

81 Introduction:

The ankle and hindfoot are essential anatomical parts for controlling body balance, and mobility. 82 If fractured, there is difficulty in ambulation and fracture pain further restricts these movements. 83 Fracture pre-and post-treatment pain control is essential to reduce patient distress, but over or sub-84 optimal treatment leads to undesired consequences and results in readmissions, prolonged 85 86 treatment, and patient dissatisfaction. Further to this, while selecting analgesics, pain control is mainly focused, ignoring potential patient harm. Parenteral analgesics are usually switched to oral 87 analgesics at the time of hospital discharge to control pain for ambulation and rehabilitation. To 88 89 optimize pain management, it is of utmost importance to choose analgesics that timely and adequately manage pain and have negligible side effects. 90

There is scarce data available on optimal pain management (including pain relief as well as 91 analgesic safety) for specific fractures in adults [1-6]. Some pain management standards like The 92 National Institute for Health and Care Excellence (NICE) guideline, Centers for Disease Control 93 and Prevention (CDC), and some research studies recommend acetaminophen as the first treatment 94 choice followed by either NSAIDs or opioids depending on fracture type, site, etc. [7, 8]. In the 95 NICE guide, pain management for ankle and foot fractures is also specified. Oral acetaminophen 96 is recommended as an initial treatment for ankle fractures. Codeine could be added for 97 uncontrolled pain with further addition of NSAIDs as required but with due care in elderly and 98 frail adults [7]. Injectable morphine might be administered in uncontrolled ankle fracture pain with 99 100 special attention in elderly and frail adults [7, 9]. Furthermore, certain research studies developed ankle and foot fracture pain management protocols with a reduced number of analgesic quantities 101 while in some studies patient satisfaction with better ankle fracture pain control was assessed [10-102

103 12]. Some randomized controlled trials were performed to assess safety and pain control by certain104 analgesics in ankle and foot fracture surgeries [13, 14].

It is essential that practitioners have sound knowledge about appropriate analgesic selection that 105 controls pain effectively and is safe. The study aims to assess the extent of pain relief and safety 106 of oral analgesic(s) routinely prescribed in ankle and foot fracture surgeries at discharge and 1-107 108 week post-discharge at a tertiary care hospital. This will allow us to identify the analysis or their combinations that either adequately control pain with better tolerance or inadequately control pain 109 with potential toxicity. The current evidence will help maximize benefit and reduce patient harm 110 111 by selecting appropriate and safe analgesics for ankle and hind foot trauma fracture pain management and thus, optimize orthopaedic surgeons analgesic prescribing practice. 112

113

114 Methods:

After obtaining Ethical Review Committees and Institutional approvals, the observational, 115 prospective cohort study was initiated in June 2022. The adult patient population with ankle or 116 hindfoot trauma fractures of any gender who arrived at a tertiary care hospital between June 2022 117 to July 2023 and were surgically managed were included. Those patients who were unable to 118 119 consent or had undergone limb amputation were excluded. The patient's written informed consent was obtained as per Good Clinical Practice guidelines before study enrollment. The demographics 120 and prescribed oral analgesics at patient discharge and 1-week follow-up were recorded. 121 122 Continuous variables like for age, normality of distribution was assessed for normality of distribution using the Shapiro Wilk test. For qualitative variables, frequency and percentages were 123 used. Patients were followed at 1- and 2-week post-discharge to assess their pain control using a 124 125 visual analogue scale (0=no pain, 1-3=mild, 4-6=moderate, and 7-10=severe pain scores) as well

as any adverse events (reported by patients or were clinically examined/identified) likely with 126 prescribed oral analgesics at discharge and 1-week follow-up respectively. Oral analgesics or their 127 combinations prescribed at discharge and 1-week follow-up were stratified. Analgesics with sub-128 optimal pain control and toxicity or with optimal pain control and tolerance were isolated. The 129 relationship of covariates age gender, and comorbid condition was evaluated between adverse 130 131 events or pain scores assessed at 1- and 2-week follow-ups using multiple logistic regression or multiple linear regression analysis respectively. The *p*-value <0.05 was considered statistically 132 significant with a confidence interval of 95%. 133

134

135 **Results:**

During almost one year time, 54 ankle and hindfoot fracture patients were enrolled in the study in
which ankle fractures 46 (85%), hindfoot 7 (13%), and both ankle and hindfoot fractures 01 (2%).
Males were 33 (61%) while females were 21 (39%). The median age was 46 (IQR=25). The most
common mechanisms of injury were falls (N=24, 44%) and road traffic accidents (N=23, 43%).
Median pain scores were 3.2 (IQR=3.0) and 2.0 (IQR=2.0) at 1- and 2-week follow-ups
respectively.

At 1 week follow-up, 25 (46%) patients were free of any AE/SAE while 29(54%) experienced either AE (N=17) or SAE (N=12) potentially due to analgesics prescribed at the time of discharge. At 2 weeks follow-up, 38(70%) patients were free of AE/SAE while 16(30%) experienced either AE (N=12) or SAE (N=04) potentially due to 1-week prescribed analgesics. No mortality was reported at both follow-ups.

147 On stratification (Figures 1 and 2), the prescribed analgesics showing toxicity and with sub-148 optimal pain control or analgesics showing better pain control and tolerance at 1- and 2-week

follow-ups were segregated. It was observed that analgesic combinations like the combination of 149 acetaminophen, tramadol, and diclofenac (N=8) showed several SAEs (N=3) and AE (N=2) with 150 moderate pain in half of the patients at follow-ups. Naproxen, acetaminophen, and pregabalin with 151 or without adding thiocolchicoside or tizanidine (N=3) showed SAE (N=1) or AE (N=1) with 152 mostly moderate pain. Adding tramadol in the analgesic combination naproxen, acetaminophen, 153 154 and pregabalin (N=2) shows AE (N=1) and mild/moderate pain. Combining naproxen, acetaminophen, and tramadol (N=2) also showed AE in both patients with mild/severe pain. 155 156 157 Figure 1: Discharge analgesics with potential SAE/AEs (A) and pain control (B). 158 Figure 2: Analgesics prescribed at 1-week follow-up with potential SAE/AEs (A) and pain control 159 160 (B). 161 Patients treated with the combination of acetaminophen and orphenadrine with or without adding 162 tramadol (N=5) experienced SAE (N=3) and AE (N=1) with inadequate pain control in the 163 majority at follow-ups. Combination of celecoxib, and acetaminophen (N=4) showed AE (N=2) 164 and no to moderate pain. If celecoxib was combined with pregabalin or tramadol (N=3) showed 165 AE (N=2) with severe pain (N=2). Meloxicam when administered alone (N=4) showed SAE (N=1) 166 and AE (N=2) with none to moderate pain. When meloxicam was combined with tramadol and 167 168 acetaminophen (N=2) showed no AE with mild/moderate pain (N=2). Tramadol, when combined with acetaminophen (N=9) produced AEs (N=4) but pain was well 169

170 controlled in these patients at follow-ups.

Some analgesics in certain analgesic combinations worked well while when combined with some other analgesics showed toxicity and inadequate pain control. Analgesic etoricoxib (N=2) had no AE/SAE and no/mild pain. Adding acetaminophen in etoricoxib (N=1) showed no AE/SAE but moderate pain. If etoricoxib was combined with tramadol or diclofenac (N=3) showed SAE (N=1) or AE (N=1) with no to moderate pain. Patients treated with diclofenac with or without acetaminophen (N=7) experienced only mild AE (N=2) with no/mild pain in the majority.

Acetaminophen (N=6) administration showed SAE (N=1) with no to moderate pain. The combination of pregabalin and acetaminophen (N=5) with or without tramadol showed no SAE/AE and pain was none or mild in the majority.

On applying multiple logistic regression, the model was non-significant for AEs assessed at 1-($X^2(3) = 0.47$, p=0.9) and 2 weeks ($X^2(3) = 3.9$, p=0.26) to covariates age (p=0.9, 0.6), gender (p=0.7, 0.6), and comorbidity binary variable (p=0.6, 0.2) with Nagelkerke R²=0.01 and 0.1, respectively. The multiple linear regression model was non-significant for pain score at 1- and 2week follow-ups and covariates age (p=0.1, CI= -0.67-0.13; p=0.9, CI= -0.03-0.03), gender (p=0.7, CI= -1.2-0.9; p=0.1, CI= -1.6-0.2), and comorbidity binary variable (p=0.1, CI= -0.2-2.3; p=0.2, CI= -0.4-1.8) with R²=0.05 and 0.07 respectively.

187

188 **Discussion:**

In the current data, it was observed that some oral analgesics prescribed to ankle or hindfoot fracture patients at discharge or at 1-week follow-up are sub-optimal in controlling pain and showed toxicity at 1- and/or 2-week follow-ups respectively. When acetaminophen, tramadol, and diclofenac were combined, several central nervous system (CNS) and cardiovascular side effects were reported like anxiety, insomnia, headache, dizziness, angina, hypotension, hypertension, etc.

with sub-optimal pain control. In the literature, diclofenac risks are reported, particularly
cardiovascular events [15, 16]. Additionally, some evidence shows that combining tramadol and
diclofenac can cause CNS and GIT side effects but contrary to our findings, better analgesia was
observed in these studies [17-19].

Another combination of naproxen, acetaminophen pregabalin with or without adding other 198 analgesics like thiocolchicoside or tizanidine or tramadol showed sub-optimal pain control with 199 GIT, cardiovascular (CVS), and CNS toxicity like hypotension, headache, anorexia, dysphagia, 200 constipation, oral ulcers, diarrhea, weakness, cough etc. Similar reports are available on tramadol 201 202 and naproxen toxicity and sub-optimal pain control on opioid use [20-27]. In addition to the above analgesic combinations, acetaminophen and orphenadrine including or not tramadol showed sub-203 optimal pain control with toxicity like hypotension, hypertension, dyspnea, sweating, dysuria, 204 205 anorexia, depression, etc. There is scarce literature available on the toxicity of this combination [28]. 206

When celecoxib and acetaminophen were combined showed better pain control in the majority and produced gastrointestinal (GIT) side effects like constipation, nausea, and vomiting. The addition of pregabalin in this combination produced CNS and GIT side effects like insomnia, constipation, diarrhea, etc. with sub-optimal pain control. Our finding is contrary to available scarce evidence of celecoxib with pregabalin being safe and effective in spinal surgery [29]. As the indication of pain management is different, the results may vary. Celecoxib toxicity is also reported for CNS, GIT, and CVS systems [30, 31].

214 Meloxicam when taken alone, one 30-year-old patient experienced SAE hypotension with no 215 underlying comorbidity. Besides this, GIT-related side effects were also observed in patients like

constipation and diarrhea. The pain was mostly well controlled. The side effects of meloxicam are 216 217 commonly related to GIT problems, but cerebrovascular side effects are also known [32-34]. Etoricoxib when combined with acetaminophen was safe with no side effects and better pain 218 control in ankle and hind foot fractures but when tramadol or diclofenac is added, the combination 219 220 showed severe CNS toxicity like memory loss, blurred vision, fatigue, dry mouth along with GIT 221 problems like anorexia, constipation, nausea with sub-optimal pain control. Few reports are available for this combination in which side effects of etoricoxib when combined with diclofenac 222 are mentioned like GIT and CNS problems including seizures, hypertension, etc. [35-38] 223 224 Analgesic pregabalin alone or with acetaminophen and tramadol showed no AE with none to moderate pain. Rare reports are available for this combination which showed better pain control 225 with AEs like somnolence, dizziness, and blurred vision [39]. 226 227 In the literature, acetaminophen is reported to be a safe analgesic [40, 41]. In the present research, mostly there was no harm observed after acetaminophen administration except for one 24-year-228 old pregnant lady with no underlying comorbidity who experienced hypotension. It was also 229 observed that pain control was sub-optimal with acetaminophen alone. The literature reports 230 similar systemic events including hypotension after taking acetaminophen [42-48]. 231 In our ankle and hindfoot fracture population, analgesic diclofenac with or without acetaminophen 232 optimally controlled pain as well as was safe in ankle and hindfoot fractures. When diclofenac was 233

combined with tramadol showed SAE/AEs but when prescribed alone or in combination withacetaminophen, it seemed safe and had better pain control.

236

237 Conclusion:

Thus, in the current ankle and hindfoot fractures data on oral analgesics management, it was 238 observed that certain analgesic combinations were sub-optimal in controlling pain and were toxic 239 like combinations of tramadol with diclofenac/naproxen; naproxen, pregabalin 240 and acetaminophen; etoricoxib with tramadol/diclofenac; orphenadrine with acetaminophen with or 241 without tramadol; and celecoxib with acetaminophen with or without tramadol/pregabalin. 242 Changing some sets of analgesic combinations were safe and had better pain control like etoricoxib 243 or diclofenac with or without combining with acetaminophen showed better tolerance and pain 244 control in ankle and hindfoot fracture patients. The current stratification of harmful and safe 245 246 analgesic combinations might assist in optimal pain management of specific fractures by selecting safe analgesics that have better pain control. 247

248

249 Limitation:

This is a single-center study and thus, the generalizability of findings was not achieved. The analgesics to AE relationship was not determined thoroughly by root cause analysis.

252

253 **Disclosure:**

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

256

257 Funding:

The study was generously supported by the Orthopaedic Trauma Association (proposal ID #6704,

259 https://ota.org/). The award was received by TA, ZM, and YM.

260

261 **Conflict of interest:**

262 The Authors declare that there are no conflicts of interest regarding the publication of this article.

263

264 Data availability:

265 On reasonable request, data will be provided.

266

267 **References:**

- 268 1. Drendel AL, Gorelick MH, Weisman SJ, Lyon R, Brousseau DC, Kim MK. A randomized
- clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture

270 pain. Ann Emerg Med. 2009;54(4): 553-560.

- Charney RL, Yan Y, Schootman M, Kennedy RM, Luhmann JD. Oxycodone versus codeine
 for triage pain in children with suspected forearm fracture: a randomized controlled trial.
 Pediatr Emerg Care. 2008;24(9): 595-600.
- 274 3. Friday JH, Kanegaye JT, McCaslin I, Zheng A, Harley JR. Ibuprofen provides analgesia
- equivalent to acetaminophen-codeine in the treatment of acute pain in children with extremity
 injuries: a randomized clinical trial. Acad Emerg Med. 2009;16(8): 711-716.
- 4. Clark E, Plint AC, Correll R, Gaboury I, Passi B. A randomized, controlled trial of
 acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal
 trauma. Pediatrics. 2007;119(3): 460-467.
- 280 5. Benhamed A, Boucher V, Emond M. Pain management in emergency department older adults
- with pelvic fracture: still insufficient. Canadian Journal of Emergency Medicine. 2022;24(3):
- **282 245-246**.

99738; this version posted December 9, 2023. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.11 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

283	6.	Apostolo	poulos A	Kiriakidis A.	Xrisantho	poulou M.	Anastaso	poulos P	, Antoniou D	, Liakou
										7

- K, et al. Parecoxib as a post surgical analgesic drug in fractures of the hip joint in comparison 284
- with diclofenac-pethidine. Orthop Procs. 2006;88-B Suppl 1:186 285
- NICE. Fractures (non-complex): assessment and management; 2016 [cited 2022 October 12]. 286 7. Available
- https://www.nice.org.uk/guidance/NG38/chapter/Recommendations#ongoing-orthopaedic-288
- management. 289

287

- Centers for Disease Control and Prevention (CDC) guidelines for prescribing opioids for pain 290 8.
- 291 - United States; 2022 2023 [updated January 31, 2023; cited 2023 March 27]. Available from:
- https://www.guidelinecentral.com/guideline/2214777/. 292
- 9. NICE. Complex fractures; 2016 [cited 2023 April 06]. Available from: 293 https://www.nice.org.uk/guidance/ng37/resources/fractures-complex-assessment-and-294
- management-pdf-1837397402053. 295
- 10. Troy Boffeli D, Catlea Gorman D. A guide to postoperative pain management. Podiatry 296 Today. 2018;31(9). 297
- 11. Xu AL, Humbyrd CJ. Strategies for Reducing Perioperative Opioid Use in Foot and Ankle 298 Surgery: Education, Risk Identification, and Multimodal Analgesia. Orthopedic Clinics. 2023. 299
- 12. Helmerhorst GTT, Lindenhovius ALC, Vrahas M, Ring D, Kloen P. Satisfaction with pain 300 relief after operative treatment of an ankle fracture. Injury. 2012;43(11): 1958-1961. 301
- 302 13. Jarde O, Boccard E. Parenteral versus Oral Route Increases Paracetamol Efficacy. Clin Drug Investig. 1997;14(6): 474-481. 303
- 14. Soulier SM, Page JC, Larsen LC, Grose BC. The efficacy of ANSAID (flurbiprofen) as an 304 305 analgesic in foot surgery. J Foot Ankle Surg. 1997;36(6): 414-417.

from:

306	15. Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as
307	compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney
308	Int. 2006;70(8): 1495-502.

- 309 16. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of
 310 nationwide cohort studies. BMJ. 2018;362: k3426.
- 311 17. Mitra S, Khandelwal P, Sehgal A. Diclofenac-tramadol vs. diclofenac-acetaminophen
 312 combinations for pain relief after caesarean section. Acta Anaesthesiol Scand. 2012;56(6):
 313 706-711.
- 18. Shareef SM, Sridhar I, Dakshayani KM, Rao YV, Santhamma B. Evaluation of the effects of
 tramadol and diclofenac alone and in combination on post-cesarean pain. Int J Basic Clin
 Pharmacol [Internet]. 2017;3(3): 470-473.
- Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitization and pain
 after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and
 in combination. Anesth Analg. 2003;97(2): 526-533.
- 20. Cossmann M, Kohnen C, Langford R, McCartney C. [Tolerance and safety of tramadol use.
- Results of international studies and data from drug surveillance]. Drugs. 1997;53 Suppl 2: 5062.
- 21. Hallberg P, Brenning G. Angioedema induced by tramadol—a potentially life-threatening
 condition. Eur J Clin Pharmacol. 2005;60(12): 901-903.
- 325 22. Dhingra H. Naproxen; 2022 [cited 2023 March 27]. Available from:
 326 https://www.buzzrx.com/naproxen-coupon/side-effects.
- 327 23. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of Opioid
- vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or

- Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA.
 2018;319(9): 872-882.
- 24. Sutton LB. Naproxen sodium. J Am Pharm Assoc (Wash). 1996;Ns36(11):663-7.
- 332 25. Al-Abri SA, Anderson IB, Pedram F, Colby JM, Olson KR. Massive naproxen overdose with
- serial serum levels. J Med Toxicol. 2015;11(1): 102-105.
- 26. Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic
 pain. Neuropsychiatr Dis Treat. 2007;3(6): 885-891.
- 27. Ho JM, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, et al. Pregabalin and
- heart failure: A population-based study. Pharmacoepidemiol Drug Saf. 2017;26(9): 10871092.
- 28. Park YS, Kim YB, Kim JM. Status epilepticus caused by nefopam. J Korean Neurosurg Soc.
 2014;56(5): 448-450.
- 29. Zhang Y, He B, Zhao J, Zhang M, Ren Q, Zhang W, et al. Addition of Celebrex and Pregabalin
- to Ropivacaine for Posterior Spinal Surgery: A Randomized, Double-Blinded, PlaceboControlled Trial. Drug Des Devel Ther. 2021;15: 735-742.
- 30. Barcella C, Lamberts M, McGettigan P, Fosbøl E, Lindhardsen J, Torp-Pedersen C, et al.
 Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A
- nationwide study in patients with osteoarthritis. Basic Clin Pharmacol Toxicol. 2018;124.
- 347 31. Searle. Product Information. Celebrex (celecoxib); 2001 [cited 2023 October 18]. Available
 348 from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20998s10lbl.pdf.
- 349 32. Khalil NY, Aldosari KF. Meloxicam. Profiles Drug Subst Excip Relat Methodol. 2020;45:
 350 159-197.

351	33. Poverennova IE, Zolotovskaya IA. [Cerebrovascular risks and prediction of complications in
352	patients with backache during therapy with nonsteroidal anti-inflammatory drugs]. Ter Arkh.
353	2015;87(5): 53-57.

- 34. Dalal D, Dubreuil M, Peloquin C, Neogi T, Zhang Y, Choi H, et al. Meloxicam and risk of
 myocardial infarction: a population-based nested case-control study. Rheumatol Int.
 2017;37(12): 2071-2078.
- 357 35. Arnao V, Riolo M, Fierro B, Aridon P. Seizure following the Use of the COX-2 Inhibitor
 358 Etoricoxib. Case Rep Neurol Med. 2017;2017: 1410759.
- 359 36. Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, et al. Gastrointestinal
- 360 side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus
- 361 Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J
 362 Rheumatol. 2007;34(2): 408-420.
- 363 37. Drugbank. Etoricoxib; 2021 [cited 2023 December 01]. [Entry 366]. Available from:
 364 https://go.drugbank.com/drugs/DB01628.
- 365 38. Thumtecho S, Wainipitapong S, Tantakitti P. Transient depersonalisation/derealisation
 366 syndrome from tramadol. BMJ Case Rep. 2023;16(6): e254909.
- 367 39. Hassab ARM, Fawzy HM, Elfawal SM, Kamaleldin DM. Comparative study between
 368 paracetamol versus paracetamol and pregabalin combination for postoperative analgesia in
 369 hip surgeries. QJM: Int J Med. 2020;113(Supplement_1).
- 40. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or
- their combination in postoperative pain management: a qualitative review. Br J Anaesth.
 2002;88(2): 199-214.

373	41. Verkleij SP, Luijsterburg PA, Bohnen AM, Koes BW, Bierma-Zeinstra SM. NSAIDs vs
374	acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity
375	influencing the outcomes. Osteoarthr Cartil. 2011;19(8): 921-929.

- 42. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal
 antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation.
 2006;113(12): 1578-1587.
- 43. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic
 analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14): 15191524.
- 44. Pezzia C, Sanders C, Welch S, Bowling A, Lee WM. Psychosocial and behavioral factors in
 acetaminophen-related acute liver failure and liver injury. J Psychosom Res. 2017;101: 5157.
- 45. Lee BT, Odin JA, Grewal P. An Approach to Drug-Induced Liver Injury from the Geriatric
 Perspective. Curr Gastroenterol Rep. 2021;23(4): 6.
- 387 46. Zyoud SH, Awang R, Sulaiman SA, Al-Jabi SW. Association between gastrointestinal
 388 manifestations following acetaminophen poisoning and outcome in 291 acetaminophen
 389 poisoning patients. Pharmacoepidemiol Drug Saf. 2010;19(5): 511-517.
- 47. Brown G. Acetaminophen-induced hypotension. Heart Lung. 1996;25(2): 137-140.
- 48. Danguy des Déserts M, Nguyen BV, Giacardi C, Commandeur D, Paleiron N.
 [Acetaminophen-induced hypotension after intravenous and oral administration]. Ann Fr
 Anesth Reanim. 2010;29(4): 313-314.



Figure 1



Figure 2